We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $54.25 · 12 analysts
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Stored first · Google News · Yahoo Finance (English)
Cogent Biosciences (COGT) Reveals Promising Phase 3 Trial Results for Bezuclastinib - GuruFocus
Cogent Biosciences (COGT) Reveals Promising Phase 3 Trial Results for Bezuclastinib GuruFocus
Analysts Offer Insights on Healthcare Companies: Staar Surgical (STAA), Cogent Biosciences (COGT) and GlaxoSmithKline (GSK) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Staar Surgical (STAA), Cogent Biosciences (COGT) and GlaxoSmithKline (GSK) The Globe and Mail
Cogent Biosciences presented detailed clinical data from its PEAK Phase III trial at the 2026 American Society of Clinical Oncology Annual Meeting. - Bitget
Cogent Biosciences presented detailed clinical data from its PEAK Phase III trial at the 2026 American Society of Clinical Oncology Annual Meeting. Bitget
Cogent Biosciences announces detailed clinical data from peak phase 3 trial with bezuclastinib in combination with sunitinib - marketscreener.com
Cogent Biosciences announces detailed clinical data from peak phase 3 trial with bezuclastinib in combination with sunitinib marketscreener.com
Cogent Biosciences Announces Detailed Clinical Data From Peak Phase 3 Trial With Bezuclastinib In Combination With Sunitinib - TradingView
Cogent Biosciences Announces Detailed Clinical Data From Peak Phase 3 Trial With Bezuclastinib In Combination With Sunitinib TradingView
Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting - GlobeNewswire
Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 04. | After market close (AMC) | $-0.57 | — | — | $0 | — | Scheduled |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 29. | Wedbush | — | Maintain | Outperform → Outperform | — | Wedbush: Outperform |
| 2026. 05. 06. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
| 2026. 03. 17. | Wedbush | — | Maintain | Outperform → Outperform | — | Wedbush: Outperform |
| 2026. 02. 18. | Piper Sandler | — | Maintain | Overweight → Overweight | — | Piper Sandler: Overweight |
| 2026. 01. 21. | Wedbush | — | Maintain | Outperform → Outperform | — | Wedbush: Outperform |
| 2026. 01. 06. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
As of FY2026Q1 · Source: SEC/DART + price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 1,410,826 | $54.3B | 0.10% | — | New position |
| 2 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 827,525 | $29.39B | 0.05% | — | New position |
| 3 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 53,090 | $2.04B | 0.00% | — | New position |
| 4 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 12,600 | $447.55M | 0.00% | — | New position |